Meciko Muharemovic, MD
Internal Medicine · Hampton Bays, NYNPI 1477640969
Payments from drug & device makers
Across 409 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$835
- Pfizer$828
- AstraZeneca$650
- Boehringer Ingelheim$554
- Amgen$436
- plus $4K from 30 others
What the payments were for
- Food & beverage$8,32199%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 58 | $1,244 |
| Lilly USA, LLC | 46 | $835 |
| Pfizer | 42 | $828 |
| AstraZeneca | 34 | $650 |
| Boehringer Ingelheim | 28 | $554 |
| Amgen | 17 | $436 |
| Novo Nordisk | 20 | $409 |
| Alkermes, Inc. | 15 | $337 |
| Johnson & Johnson | 16 | $319 |
| GSK | 14 | $295 |
| Amarin Pharma, Inc. | 14 | $252 |
| Daiichi Sankyo Inc. | 12 | $242 |
| Indivior Inc. | 11 | $236 |
| Exact Sciences | 8 | $221 |
| Astellas Pharma US Inc | 8 | $165 |
| E.r. Squibb & Sons, L.L.C. | 8 | $156 |
| Amneal Pharmaceuticals LLC | 6 | $139 |
| Abbott | 7 | $139 |
| Regeneron Healthcare Solutions, Inc. | 7 | $139 |
| Merck | 7 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $92 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| Corcept Therapeutics | 3 | $69 |
| Sanofi | 2 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $58 |
| Esperion Therapeutics, Inc. | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Sanofi Pasteur Inc. | 2 | $31 |
| Novartis | 2 | $29 |
| Metacel Pharmaceuticals LLC | 1 | $26 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Avvisto Therapeutics, LLC | 1 | $23 |
| Shield Therapeutics Inc | 1 | $22 |
| Bavarian Nordic A/s | 1 | $18 |
| Orexo US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$103
How this compares
$8,374 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 130 | $177,493 |
| EliquisApixaban | 89 | $124,926 |
| JardianceEmpagliflozin | 70 | $75,789 |
| MounjaroTirzepatide | 71 | $75,691 |
| RybelsusSemaglutide | 21 | $41,238 |
| FarxigaDapagliflozin Propanediol | 30 | $39,311 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $36,983 |
| XareltoRivaroxaban | 21 | $28,988 |
| ProliaDenosumab | 17 | $28,198 |
| Repatha SureclickEvolocumab | 15 | $14,683 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $13,006 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,286 |
| SynthroidLevothyroxine Sodium | 95 | $7,026 |
| Rosuvastatin Calcium | 388 | $6,710 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $6,650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $409 | $218,731151 claims |
| PfizerEliquis | $828 | $124,92689 claims |
| Boehringer IngelheimJardiance | $554 | $75,78970 claims |
| Lilly USA, LLCMounjaro | $835 | $75,69171 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $295 | $56,63875 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $650 | $55,91258 claims |
| Johnson & JohnsonXarelto | $319 | $28,98821 claims |
| AmgenProlia | $436 | $28,19817 claims |
| AbbVieSynthroid | $1,244 | $7,02695 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $139 | $4,467260 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Hampton Bays
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.